よりよい白血病治療のために
HOME >> JALSG業績 >> JALSG ASH抄録記録

JALSG ASH抄録記録

【抄録タイトル///全著者名///掲載誌】           (2016/2/8更新)
62.Toru Sakura, Fumihiko Hayakawa, Isamu Sugiura, Kiyotoshi Imai,
    Noriko Usui, Shin Fujisawa, Tohru Murayama, Toshiaki Yujiri, Hitoshi
    Kiyoi, Kazunori Ohnishi, Yasushi Miyazaki, Shigeki Ohtake, Yukio
    Kobayashi, Keitaro Matsuo, Tomoki Naoe///
Effectiveness of High-Dose
    MTX Therapy for Adult Ph-Negative ALL By Randomized Trial: JALSG
    ALL202-O///
Blood 2015 126:79

61.
Naoto Takahashi, Tetsuzo Tauchi, Kunio Kitamura, Koichi Miyamura,
   Yoshio Saburi, Yasuhiko Miyata, Yoshihiro Hatta, Fumihiko Kimura,
   Satoru Takada, Tetsuya Fukuda, Katsumichi Fujimaki, Maho Ishikawa,
     Itaru Matsumura, Noriko Usui, Kensuke Usuki, Yukio Kobayashi, Tomoki
     Naoe///
Around 70% of Japanese CML Patients Could Stop Imatinib
     According to a-STIM Criteria: The JALSG-STIM213 Study///
Blood 2015
    126:4035

60.
Miwa Adachi, Akihiro Takeshita, Tomohiko Taki, Shigeki Ohtake,
     Katsuji Shinagawa, Hitoshi Kiyoi, Mitsuhiro Matsuda, Masatomo Takahashi,
     Nobuhiko Emi, Yukio Kobayashi, Koichi Miyamura, Hiroyuki Fujita,
     Toru Sakura, Masako Iwanaga, Noriko Usui, Shuichi Miyawaki, Norio Asou,
     Kazunori Ohnishi, Yasushi Miyazaki, Tomoki Naoe///
Prognostic Impact of
     Chromosomal Variation in Patients with Acute Promyelocytic Leukemia (APL);
     Analysis of 775 Cases Enrolled in the Japan Adult Leukemia Study Group
     APL Studies/// Blood 2014 124:2329

59.
Shin Fujisawa, Keitaro Matsuo, Shuichi Mizuta, Hideki Akiyama,
      Yasunori Ueda, Yasutaka Aoyama, Yoshihiro Hatta, Kazuhiko Kakihana,
      Nobuaki Dobashi, Isamu Sugiura, Yasushi Onishi, Tomoya Maeda,
      Kiyotoshi Imai, Shigeki Ohtake, Yasushi Miyazaki, Kazunori Ohnishi,
      Tomoki Naoe///
Imatinib-Based Chemotherapy for Newly Diagnosed BCR–ABL
      Positive Acute Lymphoblastic Leukemia: Japan Adult Leukemia Study
      Group (JALSG) Ph+ALL208 Study/// Blood 2014 124:932


58.N Iriyama, N Asou, T Sakura, TMaeda, H Handa, M Takahashi,
      S Ohtake, Y Hatta, H Sakamaki, S Honda, Y Miyazaki, S Miyawaki,
      M Taniwaki, T Taki, S Yamaguchi, S Satou and T Naoe ///
Normal
      Karyotype-Acute Myeloid Leukemia With The CD4- CD7+ CD15+ CD34+
      Immunophenotype Is a Clinically Distinct Entity With a Favorable
      Outcome /// Blood 2013 122:2608

57.K Ishiyama, S Ohtake, H Sakamaki, Y Miyazaki, S Miyawaki,
      K Ohnishi, and T Naoe./// 
Outcomes Of Allogeneic Hematopoietic Stem
      Cell Transplantation In AML Patients Registered In Prospective Studies:
      The JALSG Experience./// Blood 2013 122:2112

56.T Ono, A Takeshita, K Shinagawa,Y Kishimoto, H Kiyoi, M Okada,
      T Yamauchi, N Emi, H Fujita, M Matsuda, F Monma, S Ohtake, CNakaseko,
    M Takahashi,Y Kimura, M Iwanaga, N Asou, and T Naoe.///
Long-Term
      Outcome Of Acute Promyelocytic Leukemia (APL) With Lower Initial
      Leukocyte Counts By Using All-Trans Retinoic Acid (ATRA) Alone For
      Remission Induction Therapy: Japan Adult Leukemia Study Group (JALSG)
      APL97 Study. /// Blood 2013 22:3950

55.K Shinagawa, S Ohtake, T Sakura, Y Ueda, M Sawa, J Miyatake,
      N Usui, M Onitsuka, Y Hatta, N Emi, S Tamaki, Y Ito, T Murayama, H Fujita,
      K Fujimaki, N Asou, A Takeshia, Y Miyazaki, S Miyawaki, K Ohnishi,
      T Naoe, and R Ohno./// A Phase III Study of New Synthetic Retinoid Tamibarotene
      (Am80) Compared with ATRA in Maintenance Therapy for Newly Diagnosed
      Acute Promyelocytic Leukemia(APL) : Japa Adult Leukemia Study Group
      (JALSG) APL204 Study./// Blood(ASH Annual Meeting Abstracts), Nov
      2012;120:410.

54.T Taki, H J Kim, S Ohtake, B S Cho, H Kiyoi, W S Min,  Asou, S Y Choi,
      Y Miyazaki, Y K Kim, H Sakamaki, J W Cheong, S Honda, S Miyawaki,
      M Taniwaki, H J Kim, T Naoe, and Y H Min./// Incidence and Clinical
      Features of Core Binding Factor Acute Myeloid Leukemia: A Collaborative
      Study of the Japan Adult Leukemia Study Group and the Korean Society
      of Hematology./// Blood(ASH Annual Meeting Abstracts), Nov 2012;
      120:2584.

53.N Iriyama, Y Hatta, J Takeuchi, Y Ogawa, S Ohtake, T Sakura,
      K Mitani, F Ishida, M Takahashi, T Maeda, T Izumi, H Sakamaki,
      MS Miyawaki, S Honda, Y Miyazaki, T Taki, M Taniwaki, and T Naoe///
      Expression of CD56 Is an Independent Prognostic Factor to Predict
      Relapse in Acute Myeloid Leukemia with t(8;21): Results of Japan
      Adult Leukemia Study Group(JALSG) AML97 Protocol./// Blood
      (ASH Annual Meeting Abstracts), Nov 2012; 120:2511.

52.T Sakura, F Hayakawa, T Yujiri, Y Aoyama, E Kondo, K Fujimaki,
      Y Ueda, S Ohtake, Y Miyazaki, S Miyawaki, K Ohnishi, and T Naoe///
      Outcome of Pediatric-Type Therapy for Philadelphia Chromosome-
      Negative Acute Lymphoblastic Leukemia(ALL) in Adolescents and
      Young Adults(AYA): A Study by the Japan Adult Leukemia Study
      Group(JALSG ALL202-U study) /// Blood(ASH Annual Meeting
      Abstracts), Nov 2012; 120: 1464.

51.S Yamaguchi, E Iwanaga, K Tokunaga, T Nanri, H Suzushima, T
      Shimomura, H Mitsuya, and Norio Asou. ///IDH2 Mutations Have
      An Unfavorable Impact in Elderly Patients with Acute Myeloid
      Leukemia. ///Blood (ASH Annual Meeting Abstracts), Nov 2011;
      118: 2519.

50.H Fujita, N Asou, M Iwanaga, R Hyo, S Nomura, H Kiyoi, M Okada,
      M Tsuzuki, M Matsuda, T Yamauchi,S Ohtake, T Izumi, C Nakaseko,
      K Mitani, K Shinagawa, A Takeshita, Y Miyazaki, K Ohnishi, S
      Miyawaki,and Tomoki Naoe. ///Role of Hematopoietic Stem Cell
      Transplantation As Salvage Treatment of Acute Promyelocytic
      Leukemia Initially Treated with All-Trans-Retinoic Acid: A
      Retrospective Analysis of the Japan Adult Leukemia Study Group
      (JALSG) APL97 Study ///Blood (ASH Annual Meeting Abstracts),
       Nov 2011; 118: 2036.

49.T Ono,A Takeshita, Y Kishimoto, H Kiyoi, M Okada, T Yamauchi, M
      Tsuzuki, K Horikawa, M Matsuda, K Shinagawa, F Monma, S
      Ohtake, C Nakaseko, M Takahashi, F Yagasaki, Y Kimura, H Fujita,
      M Iwanaga, N Asou, K Ohnishi, and Tomoki Naoe. ///Clinical
      Features and Prognostic Impact of CD56 Expression in Acute
      Promyelocytic Leukemia: Long Term Follow up Data From the
      Japan Adult Leukemia Study Group(JALSG) APL97 ///Blood
   (ASH Annual Meeting Abstracts), Nov 2011; 118: 3608.

 48.A Takeshita, T Ono, Y Kojima,T Kyo, N Asou, H Suzushima, F
      Yagasaki, T Maeda,M Okada, C Nakaseko, H Kanbayashi, M
      Yamaguchi, M Kurosawa,K Tsuboi, T Yujiri, Y Nannya, N Uike, N
      Akiyama, T Fukuda, K Karimata, H Okumura, T Eto, K Izumiyama, A
      Watanabe, N Aotsuka, K Ito, K Ozaki, and Tomoki Naoe.
      ///Efficacy of Gemtuzumab Ozogamicin (GO) Monotherapy on
      Relapsed/Refractory Acute Promyelocytic Leukemia (APL)
      ///Blood (ASH Annual Meeting Abstracts), Nov 2011; 118: 1532.

 47.S Kako, S Morita, H Sakamaki, H Iida, M Kurokawa, K Miyamura, H
      Kanamori, M Hara, N Kobayashi, Y Morishima, K Kawa, T Kyo, T
      Sakura, I Jinnai, J Takeuchi, Y Miyazaki, S Miyawaki, K Ohnishi, T
      Naoe, and Y Kanda ///A Decision Analysis of Unrelated
      Hematopoietic Stem Cell Transplantation for Adult Patients with
      Philadelphia Chromosome-Negative Acute Lymphoblastic
      Leukemia In First Remission Who Lack An HLA-Matched Sibling
      ///Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 3527.

 46.T Ono, A Takeshita, Y Kishimoto, H Kiyoi, M Okada, Y Kawai, M
      Tsuzuki, K Horikawa, M Matsuda, K Shinagawa, F Monma, S
      Ohtake, C Nakaseko, M Takahashi, F Yagasaki,  Y Kimura, M
      Iwanaga, N Asou, T Naoe, and R Ohno ///Clinical Features and
      Outcomes of Elderly Patients with Acute Promyelocytic Leukemia
      (APL) - the Japan Adult Leukemia Study Group APL97 Study.
      ///Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 1077.

 45.H Shimizu, T Saitoh, T Hoshino, N Hatsumi, S Takada, H Irisawa, A
      Yokohama, T Jimbo, H Handa, T Matsushima, T Sakura, N
      Tsukamoto, M Karasawa, H Murakami, and S Miyawaki ///Clinical
      Significance of Granulocytic Sarcoma at Relapse In Adult Patients
   with Acute Myeloid Leukemia ///Blood (ASH Annual Meeting
      Abstracts), Nov 2010; 116: 4373.

 44.C Nakaseko, K Ohnishi, J Takeuchi, S Fujisawa, T Nagai, S Ohtake,
      H Yamazaki, T Tauchi, K Imai, N Mori, F Yagasaki, H Akiyama, Y
      Maeda, N Usui, Y Saburi, T Ishida, H Kosugi, K Miyamura, Y
      Miyazaki, H Handa, A Yokota, K Matsumoto, K Fujimaki, T Matsui, H
      Kiyoi, S Miyawaki, R Ohno, and T Naoe ///Sustained Superior
      Long-Term Outcomes of Imatinib Therapy In Japanese Patients
      with Newly Diagnosed Chronic Myelogenous Leukemia In Chronic
      Phase: Sub-Analysis According to the Mean Daily Dose of Imatinib
      and the Plasma Trough Levels In JALSG CML202 Study After 66
      Months Follow-up. ///Blood (ASH Annual Meeting Abstracts), Nov
      2010; 116: 3417.

  43.Usui N, Takeshita A, Nakaseko C, Dobashi N, Fujita H, Kiyoi H,
      Kobayashi Y, Fujisawa S, Yagasaki F, Nishii K, Kiguchi T, Miyazaki Y,
      Ohtake S, Miyawaki S, Ohno R, Naoe T, and Ohnishi K. ///A Phase
      I/II Trial of Gemtuzumab Ozogamicin in Combination with
      Cytarabine and Anthracyclines (Daunorubicin or Idarubicin) for
      CD33-Positive Refractory or Relapsed AML Patients Younger
      Than 65 Years. Results of Phase I Parts of the JALSG-AML206
      Study. ///Blood (ASH Annual Meeting Abstracts), Nov 2009; 114:
      4145.

 42.Jinnai I, Sakura T, Tsuzuki M, Maeda Y, Usui N, Kato M, Okumura
      H, Ueda Y, Kishimoto Y, Yagasaki F, Takeuchi J, Iwanaga M,
      Miyazaki Y, Miyawaki S, Ohnishi K, Naoe T, and Ohno R
      ///Outcome by Treatment Including An Intensified Consolidation
      Program with Dose-Escalated Doxorubicin for Newly Diagnosed
      Acute Lymphoblastic Leukemia (ALL): A Study by the Japan Adult
      Leukemia Study Group (JALSG ALL97 study). ///Blood (ASH
      Annual Meeting Abstracts), Nov 2009; 114: 4334.

 41.Miyawaki S, Hatsumi N, Yamauchi T, Tsuboi K, Fujieda A, Takeshita
      A, Komatsu N, Usui N, Arai Y, Ishida F, Morii T, Kano Y, Ogura M,
      Doki N, Ohnishi K, Naoe T, and Ohno R ///Phase 2 Study of
      FLAGM (Fludarabine+High-Dose Ara-C +G-CSF+Mitoxantrone) for
      Relapsed or Refractory Acute Myeloid Leukemia (AML): A Report
      From the Japan Adult Leukemia Study Group (JALSG). ///Blood
      (ASH Annual Meeting Abstracts), Nov 2009; 114: 1058.

 40.Promising Outcome of Imatinib-Combined Chemotherapy Followed
      by Allogeneic Hematopoietic Stem Cell Transplantation for
      Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia:
      Results of the Japan Adult Leukemia Study Group (JALSG)
      Ph+ALL202 Regimen. ///Hatta Y, Mizuta S, Ohtake S, Sugiura I,
      Ueda Y, Kanamori H, Akiyama H, Takeuchi M, Usui N, Yujiri T,
      Fujieda A, Kiguchi T, Jinnai I, Naoe T, and Ohno R ///Blood (ASH
      Annual Meeting Abstracts), Nov 2009; 114: 3090.

 39.Updated Results of JALSG AML201 Study Comparing Intensified
      Daunorubicin with Idarubicin in Patients with De Novo Acute
      Myeloid Leukemia: Effect of Hematopoietic Stem Cell
      Transplantation./// Ohtake S, Miyawaki S, Fujita H, Kiyoi H,
      Shinagawa K, Usui N, Miyamura K, Nishimura M, Miyazaki Y, Nishii
      K, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura
      Y, Asou N, Honda S, Ohnishi K, Naoe T, and Ohno R.///Blood (ASH
      Annual Meeting Abstracts), Nov 2008; 112: 2171.

 38.A Randomized Trial Comparing Individualized Vs. Non-Individualized
      Treatment for Elderly Acute Myeloid Leukemia: JALSG GML200
      Study/// Wakita A, Ohtake S, Takada S, Yagasaki F, Komatsu H,
      Miyazaki Y, Kubo K, Kimura Y, Takeshita A, Adachi Y, Kiyoi H,
      Yamaguchi T, Yoshida M, Ohnishi K, Miyawaki S, Naoe T, Ueda R,
      and Ohno R.///Blood (ASH Annual Meeting Abstracts), Nov 2008;
      112: 2961.

 37.Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation
      during First Complete Remission Following Imatinib-Combined
      Chemotherapy in Patients with Philadelphia Chromosome-Positive
      Acute Lymphoblastic Leukemia./// Mizuta S, Yanada M, Sugiura I,
      Yagasaki F, Yujiri T, Takeuchi M, Hatta Y, Kimura Y, Ueda Y,
      Kanamori H, Usui N, Akiyama H, Miyazaki Y, Ohtake S, Jinnai I,
      Matsuo K, Naoe T, and Ohno R.///Blood (ASH Annual Meeting
      Abstracts), Nov 2008; 112: 462.

 36.Long-Term Follow-up of the Randomized JALSG AML 201 Study
      Comparing High Dose Ara-C Therapy with Conventional
      Consolidation Therapy in Adult Acute Myeloid Leukemia
      (AML)///Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K,
      Usui N, Miyamura K, Nishimura M, Miyazaki Y, Nishii K, Tadashi
      Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y,
      Asou N, Honda S, Ohnishi K, Naoe T, and Ohno R.///Blood (ASH
      Annual Meeting Abstracts), Nov 2008; 112: 135.

 35.Allogeneic Stem Cell Transplantation (Allo-SCT) in Adults with
      Acute Myelogenous Leukemia (AML). Final Analysis of JALSG
      AML97 Study/// Sakamaki H, Miyawaki S, Ohtake S, Emi N,
      Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N,
      Takahashi M, Ogawa Y, Honda S, and Ohno R.///Blood (ASH
      Annual Meeting Abstracts), Nov 2008; 112: 347.

 34.Factors associated with relapse-free survival in patients with
      Philadelphia chromosome-positive acute lymphoblastic leukemia
      treated with imatinib-combined chemotherapy /// Yanada M.
      Takeuchi J. Sugiura I. Akiyama H. Usui N. Yagasaki F. Nishii K. Ueda
      Y. Takeuchi M. Miyawaki S. Maruta A. Narimatsu H. Miyazaki Y.
      Ohtake S. Jinnai I. Matsuo K. Naoe T. Ohno R. /// BLOOD 110
      (11):827A-828A 2813 2007

 33.Randomized clinical trial of induction therapy comparing intensified
      daunorubicin with idarubicin in patients with previously untreated
      de novo acute myeloid leukemia (JALSG AML201 study). ///
      Ohtake S. Miyawaki S. Fujita H. Kiyoi H. Shinagawa K. Usui N.
      Miyamura K. Nishimura M. Miyazaki Y. Nishii K. Nagai T. Yamane T.
      Taniwaki M. Takahashi M. Yagasaki F. Kimura Y. Asou N. Honda S.
      Ohnishi K. Naoe T. Ohno R. /// BLOOD 108 (11):566A-566A 2000
      2006

 32.Detection of BCR-ABL transcript by quantitative real-time PCR
      and Amp-CML (Transcript mediated amplification) during imatinib
      therapy for chronic myeloid leukemia. /// Miyamura K. Yagasaki F.
      Kyo T. Ohnishi K. Naoe T. Takeuchi J. Nishimura M. Fujiwara S.
      Tauchi T. Ohno R. /// BLOOD 108 (11):282B-282B 4791 2006

 31.Postremission therapy in adult acute myeloid leukemia (AML): A
      randomized comparison between high dose ara-C therapy and
      conventional consolidation therapy (JALSG AML 201 study). ///
      Miyawaki S. Ohtake S. Fujisawa S. Kiyoi H. Shinagawa K. Usui N.
      Miyamura K. Nishimura M. Miyazaki Y. Nishii K. Nagai T. Yamane T.
      Taniwaki M. Takahashi M. Yagasaki F. Kimura Y. Asou N. Honda S.
      Ohnishi K. Naoe T. Ohno R. /// BLOOD 108 (11):567A-567A 2005
      2006

 30.A randomized study with or without intensified maintenance
      chemotherapy in patients with acute promyelocytic leukemia who
      had become negative for PML-RAR alpha transcript after
      consolidation therapy: The Japan adult leukemia study group
      (JALSG) APL97 study. /// Asou N. Kishimoto Y. Kiyoi H. Okada M.
      Kawai Y. Tsuzuki M. Horikawa K. Matsuda M. Shinagawa K.
      Kobayashi T. Ohtake S. Nishimura M. Takahashi M. Yagasaki F.
      Takeshita A. Kimura Y. Iwanaga M. Naoe T. Ohno R. /// BLOOD
      108 (11):569A-569A 2009 2006

 29.High complete remission rate and promising outcome by
      combination of imatinib and chemotherapy for newly diagnosed
      BCR-ABL-positive acute lymphoblastic leukemia /// Yanada M.
      Takeuchi J. Sugiura I. Akiyama H. Usui N. Yagasaki F. Emi N.
      Miyazaki Y. Ohtake S. Jinnai I. Matsuo K. Naoe T. Ohno R. ///
      BLOOD 106 (11):520A-520A 1827 2005

 28.Pharmacokinetics of arsenic species with relapsed or refractory
      acute promyelocytic leukemia (APL) treated with arsenic trioxide
      (ATO) in Japanese patients. /// Shigeno K. Kobayashi M. Sahara
      N. Nakamura S. Fujisawa S. Naito K. Shinjo K. Takeshita A. Ohno R.
      Kinoshita K. Shimoya M. Kaise T. Ohnishi K. /// BLOOD 106
      (11):185B-185B 4426 2005

 27.A new scoring system to predict the prognosis of patients with
      acute myeloid leukemia. Study from the Japan Adult Leukemia
      Study Group. /// Miyazaki Y. Nishida K. Kuriyama K. Taniwaki M.
      Sakamaki H. Miyawaki S. Ohtake S. Honda S. Tomonaga M. Ohno R.
      /// BLOOD 106 (11):667A-668A 2373 2005

 26.Triphasic exponential decline of BCR-ABL transcripts during
      imatinib therapy for chronic myelogenous leukemia. /// Miyamura
      K. Ohnishi K. Naoe T. Takeuchi J. Yoshiki N. Yagasaki F. Fujisawa S.
      Kimura Y. Motoji T. Imai K. Yamane T. Yoshida S. Miyawaki S.
      Saburi Y. Kitamura K. Ohno R. /// BLOOD 106 (11):322A-322A
      1107 2005

 25.Prognosis of acute myeloid leukemia with translocation (8;21): A
      survey of 142 cases investigated in the JALSG AML97 study. ///
      Hatsumi N. Miyawaki S. Sakamaki H. Ohtake S. Yagaski F.
      Mitani K. Matsuda S. Kishimoto Y. Miyazaki Y. Asou N. Honda S. Taniwaki M.
      Ohno R. /// BLOOD 106 (11):206B-206B 4511 2005

 24.Combination of intensive chemotherapy and imatinib (IDEAMOP
      regimen) for the treatment of newly diagnosed BCR-ABL positive
      acute lymphoblastic leukemia; Excellent efficacy without increasing
      toxicity. /// Yanada M. Emi N. Usui N. Takeuchi J. Sugiura I.
      Takeuchi M. Kobayashi T. Yagasaki F. Ohtake S. Matsuo K. Naoe T.
      Ohno R. Japan Adult Leukemia Study Grp /// BLOOD 104
      (11):748A-748A 2736 2004

 23.P-glycoprotein is related to the achievement of complete
      remission but not to disease-free survival in adult acute
      lymphoblastic leukemia: A prospective analysis in the
      JALSG-ALL97 study /// Takeshita A. Ohnishi K. Miyazaki Y. Jnnai
      I. Miyawaki S. Takahashi M. Murakami  T. Inoue N. Tanaka J. Asou
      N. Kobayashi Y. Ueda R. Ohno R. /// BLOOD 104 (11):311A-311A
      1095 2004

 22.Postremission treatment with chemotherapy or allogeneic stem
      cell transplantation (allo-SCT) in adults with acute myeloid
      leukemia (AML) - JALSG AML-97 trial. /// Sakamaki H. Miyawaki
      S. Kishimoto Y. Miyazaki Y. Asou N. Ogawa Y. Honda S. Ohno R.
      /// BLOOD 104 (11):632A-632A 2298 2004

 21.Postremission therapy in adult acute myeloid leukemia (AML): A
      randomized comparison of intensified consolidation therapy without
      maintenance therapy against conventional consolidation with
      maintenance therapy -JALSG AML-97 trial. /// Miyawaki S.
      Ohtake S. Yagasaki F. Mitani K. Matsuda S. Kishimoto Y. Miyazaki
      Y. Asou N. Ogawa Y. Honda S. Ohno R. /// BLOOD 104
      (11):248A-248A 868 2004

 20.Validation study on the prediction of response to imatinib mesylate
      in chronic myeloid leukemia (CML) patients by genome-wide cDNA
      microarray analysis. /// Kagami Y. Katagiri T. Kaneta Y. Tsuruo T.
      Nakamura Y. Ohno R. /// BLOOD 104 (11):805A-805A 2946 2004

 19.Prospective study of P-glycoprotein, multidrug resistance
      associated protein and lung resistance related protein expression
      in acute myeloid leukemia treated with the JALSG-AML95
      protocol. /// Takeshita A. Shinjo K. Ohnishi K. Miyawaki S.
      Kishimoto Y. Okada M. Mitani K. Asou N. Komatsu N. Kobayashi Y.
      Jinnai I. Ohtake S. Ueda R. Ohno R. /// BLOOD 102
      (11):605A-605A 2233 2003

 18.Biological and clinical significance of the FLT3 transcript level in
      acute myeloid leukemia. /// Ozeki K. Kiyoi H. Ueda R. Ohno R. Emi
      K. Naoe T. /// BLOOD 102 (11):575A-576A 2119 2003

 17.Cytogenetic heterogeneity of acute myeloid leukemia with
      trilineage dysplasia - JALSG-AML 92 study. /// Tomonaga M.
      Kuriyama K. Miyazaki Y. Miyawaki S. Ohtake S. Sakamaki H.
      Matsuo T. Emi N. Kobayashi T. Matsushima T. Shinagawa K. Ohno
      R. /// BLOOD 100 (11):335A-335A 1298 2002

 16.Arsenic trioxide therapy for relapsed or refractory Japanese
      patients with acute promyelocytic leukemia /// Shigeno K.
      Nakamura S. Naito K. Yoshida H. Fujisawa S. Shinjo K. Fujita Y.
      Matsui H. Sahara N. Takeshita A. Ohno R. Ohnishi K. /// BLOOD
      100 (11):264B-264B 4583 2002

 15.The percentage of myeloperoxidase-positive blast cells is a strong
      independent prognostic factor in acute myeloid leukemia, even in
      the patients with normal karyotype - JALSG-AML92 study. ///
      Miyazaki Y. Matsuo T. Kuriyama K. Yoshida S. Tomonaga M. Emi N.
      Kobayashi T. Miyawaki S. Matsushima T. Shinagawa K. Honda S.
      Ohno R. /// BLOOD 100 (11):334A-334A 1297 2002

 14.Myeloid/NK cell precursor acute leukemia is a distinct subtype of
      AML M0. /// Suzuki R. Murata M. Kami M. Ohtake S. Asou N.
      Kodera Y. Seto M. Hamajima N. Shimoyama M. Ohno R. Morishima
      Y. Nakamura S. /// BLOOD 98 (11):460A-460A 1926 Part 1 2001

 13.Multicenter prospective study of interferon-alpha versus bone
      marrow transplantation for newly diagnosed patients with chronic
      myelogenous leukemia: An interim analysis of the Kouseisho
      leukemia study group. /// Ohnishi K. Ino T. Kishimoto Y. Usui N.
      Shimazaki C. Ohtake S. Ohno R. /// BLOOD 98 (11):348A-348A
      1468 Part 1 2001

 12.Standard dose of idarubicin and cytarabine is highly effective
      remission induction therapy for the patients with therapy-related
      leukemia (TRL): A result of multiinstitutional phase II study. ///
      Yokozawa T. Takeyama K. Fukushima T. Uike N. Nagata K. Kagami
      Y. Ohno R. Saito H. Ueda R. /// BLOOD 94 (10):298A-298A 1329
      Part 1 Suppl. 1 1999

 11.Good prognosis of patients with acute promyelocytic leukemia
      (APL) who obtained second complete remission (CR) by a new
      retinoid, AM80, for relapse from CR induced all -trans retinoic
      acid. /// Takeshita A. Naito K. Miyawaki S. Takeuchi M. Ueda R.
      Ohno R. /// BLOOD  94 (10):506A-506A 2264 Part 1 Suppl. 1 1999

 10.Combination chemotherapy with risk factors-adjusted dose
      attenuation for high-risk myelodysplastic syndromes and their
      leukemia in the japan adult leukemia study group. /// Okamoto T.
      Kanamaru A. Shimazaki C. Motoji T. Takemoto Y. Ohno R. Japan
      Luekemia Study Grp /// BLOOD 94 (10):307A-307A 1375 Part 1
      Suppl. 1 1999

   9.Randomized clinical trial of response-oriented individualized versus
      fixed schedule induction chemotherapy in adult acute myeloid
      leukemia: The JALSG AML95 study. /// Ohtake S. Miyawaki S.
      Tanimoto M. Kuriyama K. Matusda S. Hatake K. Kishimoto Y.
      Takemoto Y. Takahashi M. Tamura J. Takeuchi J. Kageyama S.
      Kanamaru A. Asou N. Ohno R. /// BLOOD 94 (10):298A-298A
      1330 Part 1 Suppl. 1 1999

   8.The JALSG APL92 study for newly diagnosed acute promyelocytic
      leukemia (APL): Analysis of prognostic factors to increase cure
      rate in the next study. /// Ohno R. Asou N. Kanamaru A. Miyawaki
      S. Ohtake S. Tomonaga M. /// BLOOD 94 (10):505A-505A 2262
      Part 1 Suppl. 1 1999

   7.Randomized study of individualized induction therapy with or
      without etoposide in adult acute myeloid leukemia (except for M3)
      (JALSG-AML92 study) and analysis of prognostic factors. ///
      Miyawaki S. Tanimoto M. Kobayashi T. Minami S. Tamura J. Hatake
      K. Kuriyama K. Ohmoto E.. Saito K. Kanamaru A. Oho H. Ohtake S.
      Jinnai I. Sakamaki H. Yamada O. Asou N. Takahashi M. Takeyama
      K. Matsuda S. Ueda R. Ohno R. /// BLOOD 90 (10):2244-2244
      Part 1 Suppl. 1 1997

   6.JALSG-AML92 for newly diagnosed acute promyelocytic leukemia
      (APL) with all-trans retinoic acid (ATRA) followed by intensive
      consolidation acid maintenance/intensification chemotherapy:
      Prognostic factors for remission and survival /// Ohno R. Asou N.
      Kanamaru A. Adachi K. Miyawaki S. Kageyama S. Hiraoka A.
      Ohmoto E. Sakamaki H. Tsubaki K. Saito K. Kuriyama K. Oh H.
      Kitano Y. /// BLOOD 88 (10):1157-1157 Part 1 Suppl. 1 1996

   5.Macrophage-colony stimulating factor (M-CSF) reduces the
      incidence and duration of febrile neutropenia and shortens the
      period required to finish three courses of intensive consolidation
      therapy in acute myeloid leukemia (AML): A double-blind controlled
      study /// Ohno R. Miyawaki S. Hatake K. Tomonaga M. Kobayashi
      T. Tanimoto M. Masaoka T. Miura Y. Takaku F. Ohashi Y. Motoyoshi
      K. /// BLOOD 86 (10):1050-1050 1995

   4.Is chemotherapy or HLA-identical sibling bone marrow transplant
      better in adults with acute lymphoblastic leukemia (ALL) in first
      remission?. /// Oh H. Ohno R. Tanimoto M. Tomonaga M. Murakami
      H. Ino T. Zhang MJ. Horowitz MM. Gale RP /// BLOOD 86
      (10):2456-2456 Suppl. 1 1995

   3.Molecular analysis of the t(15;17) translocation in de novo and
      secondary acute promyelocytic leukemia /// Naoe T. Kudo K.
      Yoshida H. Horibe K. Ohno, R /// BLOOD 86 (10):2933-2933 1995

   2.All-trans-retinoic acid for the treatment of newly-diagnosed acute
      promyelocytic leukemia-response /// Kanamaru A. Ohno R. ///
      BLOOD 86 (4):1645-1645 1995

   1.Randomized trial between behenoyl cytarabine (BHAC) or
      cytarabine in combination chemotherapy of adult acute myeloid-
      leukemia (AML) (JALSG-AML89 protocol) and analysis of
      prognostic factors /// Kobayashi T. Miyawaki S. Tanimoto M.
      Kuriyama K. Murakami H. Yoshida M. Kodera Y. Minato K. Tsubaki
      K. Ohmoto E. Oh H. Jinnai I. Sakamaki H. Hiraoka A. Kanamaru A.
      Takahashi I. Furusawa S. NaoeT. Yamada O. Asou N. Nishikawa K.
      Okabe K. Ogura M. Tanaka M. Ohno R. /// BLOOD 84
      (10):A146-A146 Suppl. 1 1994